相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Challenges and opportunities for hepatitis C drug development in HIV-hepatitis C virus-co-infected patients
Vincent Soriano et al.
AIDS (2011)
Relationship Between Adherence to Hepatitis C Virus Therapy and Virologic Outcomes
Vincent Lo Re et al.
ANNALS OF INTERNAL MEDICINE (2011)
Natural polymorphisms associated with resistance to new antivirals against HCV in newly diagnosed HIV-HCV-coinfected patients
Ana Trevino et al.
ANTIVIRAL THERAPY (2011)
TELAPREVIR-BASED REGIMENS SUBSTANTIALLY IMPROVED SVR RATES ACROSS ALL IL28B GENOTYPES IN THE ADVANCE TRIAL
Ira M. Jacobson et al.
GASTROENTEROLOGY (2011)
Recombinant HCV Variants With NS5A From Genotypes 1-7 Have Different Sensitivities to an NS5A Inhibitor but Not Interferon-α
Troels K. H. Scheel et al.
GASTROENTEROLOGY (2011)
Noninvasive Assessment of Liver Fibrosis
Stella M. Martinez et al.
HEPATOLOGY (2011)
Second-Phase Hepatitis C Virus RNA Decline During Telaprevir-Based Therapy Increases With Drug Effectiveness: Implications for Treatment Duration
Jeremie Guedj et al.
HEPATOLOGY (2011)
Hepatitis C virus (HCV) protease variability and anti-HCV protease inhibitor resistance in HIV/HCV-coinfected patients
P. Trimoulet et al.
HIV MEDICINE (2011)
Directly acting antivirals against hepatitis C virus
Vincent Soriano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
Impact of antiretroviral therapy on the variability of the HCV NS5B polymerase in HIV/HCV co-infected patients
Zulema Plaza et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2011)
EASL Clinical Practice Guidelines: Management of hepatitis C virus infection
JOURNAL OF HEPATOLOGY (2011)
CHARACTERIZATION OF VIROLOGIC ESCAPE IN HCV GENOTYPE 1 NULL RESPONDERS RECEIVING A COMBINATION OF THE NS3 PROTEASE INHIBITOR BMS-650032 AND NS5A INHIBITOR BMS-790052
F. McPhee et al.
JOURNAL OF HEPATOLOGY (2011)
ONCE DAILY DUAL-NUCLEOTIDE COMBINATION OF PSI-938 AND PSI-7977 PROVIDES 94% HCVRNA <LOD AT DAY 14: FIRST PURINE/PYRIMIDINE CLINICAL COMBINATION DATA (THE NUCLEAR STUDY)
E. Lawitz et al.
JOURNAL OF HEPATOLOGY (2011)
Potency, safety, and pharmacokinetics of the NS3/4A protease inhibitor BI201335 in patients with chronic HCV genotype-1 infection
Michael P. Manns et al.
JOURNAL OF HEPATOLOGY (2011)
Hepatitis C virus resistance to protease inhibitors
Philippe Halfon et al.
JOURNAL OF HEPATOLOGY (2011)
Natural variation in drug susceptibility to HCV polymerase inhibitors in treatment-naive HCV patient isolates
S. -C. C. Sun et al.
JOURNAL OF VIRAL HEPATITIS (2011)
Boceprevir for Untreated Chronic HCV Genotype 1 Infection
Fred Poordad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A New Era of Hepatitis C Therapy Begins
Donald M. Jensen
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Response-Guided Telaprevir Combination Treatment for Hepatitis C Virus Infection
Kenneth E. Sherman et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Boceprevir for Previously Treated Chronic HCV Genotype 1 Infection
Bruce R. Bacon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Retreatment of HCV Infection
Stefan Zeuzem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir for Previously Untreated Chronic Hepatitis C Virus Infection
Ira M. Jacobson et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Telaprevir Is Effective Given Every 8 or 12 Hours With Ribavirin and Peginterferon Alfa-2a or-2b to Patients With Chronic Hepatitis C
Patrick Marcellin et al.
GASTROENTEROLOGY (2011)
Association of a single nucleotide polymorphism near the interleukin-28B gene with response to hepatitis C therapy in HIV/hepatitis C virus-coinfected patients
Norma I. Rallon et al.
AIDS (2010)
Susceptibility of Treatment-Naive Hepatitis C Virus (HCV) Clinical Isolates to HCV Protease Inhibitors
Andrew Bae et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2010)
Genetic Variation in IL28B Is Associated With Chronic Hepatitis C and Treatment Failure: A Genome-Wide Association Study
Andri Rauch et al.
GASTROENTEROLOGY (2010)
Resistance to Direct Antiviral Agents in Patients With Hepatitis C Virus Infection
Christoph Sarrazin et al.
GASTROENTEROLOGY (2010)
Viral resistance to specifically targeted antiviral therapies for hepatitis C (STAT-Cs)
Tara L. Kieffer et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
New directly acting antivirals for hepatitis C: potential for interaction with antiretrovirals
Kay Seden et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2010)
Oral combination therapy with a nucleoside polymerase inhibitor (RG7128) and danoprevir for chronic hepatitis C genotype 1 infection (INFORM-1): a randomised, double-blind, placebo-controlled, dose-escalation trial
Edward J. Gane et al.
LANCET (2010)
Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect
Min Gao et al.
NATURE (2010)
DEB025 (Alisporivir) Inhibits Hepatitis C Virus Replication by Preventing a Cyclophilin A Induced Cis-Trans Isomerisation in Domain II of NS5A
Lotte Coelmont et al.
PLOS ONE (2010)
GT-1a or GT-1b Subtype-Specific Resistance Profiles for Hepatitis C Virus Inhibitors Telaprevir and HCV-796
Matthew F. McCown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
New Therapies for Hepatitis C Virus Infection
Vincent Soriano et al.
CLINICAL INFECTIOUS DISEASES (2009)
Hepatitis C Virus Drug Resistance and Immune-Driven Adaptations: Relevance to New Antiviral Therapy
Silvana Gaudieri et al.
HEPATOLOGY (2009)
Genetic variation in IL28B predicts hepatitis C treatment-induced viral clearance
Dongliang Ge et al.
NATURE (2009)
IL28B is associated with response to chronic hepatitis C interferon-α and ribavirin therapy
Vijayaprakash Suppiah et al.
NATURE GENETICS (2009)
Genome-wide association of IL28B with response to pegylated interferon-α and ribavirin therapy for chronic hepatitis C
Yasuhito Tanaka et al.
NATURE GENETICS (2009)
Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection
John G. McHutchison et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
The hepatitis C virus replicon presents a higher barrier to resistance to nucleoside analogs than to nonnucleoside polymerase or protease inhibitors
Matthew F. McCown et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2008)
Naturally Occurring Dominant Resistance Mutations to Hepatitis C Virus Protease and Polymerase Inhibitors in Treatment-Naive Patients
Thomas Kuntzen et al.
HEPATOLOGY (2008)
Why are there different dynamics in the selection of drug resistance in HIV and hepatitis B and C viruses?
Vincent Soriano et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2008)
Natural prevalence of hepatitis C virus variants with decreased sensitivity to NS3•4A protease inhibitors in treatment-naive subjects
Doug J. Bartels et al.
JOURNAL OF INFECTIOUS DISEASES (2008)
Care of patients coinfected with HIV and hepatitis C virus:: 2007 updated recommendations from the HCV-HIV International Panel
Vincent Soriano et al.
AIDS (2007)
Dynamic hepatitis C virus genotypic and phenotypic changes in patients treated with the protease inhibitor telaprevir
Christoph Sarrazin et al.
GASTROENTEROLOGY (2007)
The hepatitis C virus life cycle as a target for new antiviral therapies
Jean-Michel Pawlotsky et al.
GASTROENTEROLOGY (2007)
Replication fitness and NS5B drug sensitivity of diverse hepatitis C virus isolates characterized by using a transient replication assay
SW Ludmerer et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2005)
Peginterferon-α2a and ribavirin combination therapy in chronic hepatitis C -: A randomized study of treatment duration and ribavirin dose
SJ Hadziyannis et al.
ANNALS OF INTERNAL MEDICINE (2004)
Duration and fitness dependence of quasispecies memory
CM Ruíz-Jarabo et al.
JOURNAL OF MOLECULAR BIOLOGY (2002)
分享论文
